William Blair Starts Coverage on Vertical Aerospace With Bullish View
William Blair begins coverage of Vertical Aerospace with an Outperform rating, highlighting its strong position in the growing urban air mobility market.
NOTRELOAD AI
Oppenheimer & H.C. Wainwright Bullish on LEGN, JBIO, CGEN
Oppenheimer and H.C. Wainwright start coverage on Legend Biotech, Jade Biosciences, and Compugen with bullish ratings and price targets, highlighting growth potential in CAR-T therapy, autoimmune, and immuno-oncology pipelines.
FDA Grants Priority Review for Atacicept IgAN Treatment
Vera Therapeutics receives FDA Priority Review for atacicept, a potential first-in-class treatment for IgA nephropathy with a decision expected by July 2026.
Major Biotech Upgrades and Coverage Initiations: Regeneron, Erasca, Protara, Design Therapeutics, Oric
Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities.
Ascentage Pharma's New Cancer Drug Gets FDA Green Light for Clinical Trials
Ascentage Pharma receives FDA clearance for APG-3288, an innovative BTK protein degrader designed to treat resistant blood cancers through a novel degradation approach.
Celsius Named Needham’s Top Stock Pick for 2026
Needham names Celsius as a 2026 Top Pick, citing strong energy drink demand, expanded distribution, and a $70 price target.